Clinical Edge Journal Scan

New predictive markers for risk of HCC in cirrhotic chronic hepatitis B


 

Key clinical point : Serum Prothrombin Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) and alpha-fetoprotein were significant predictors of hepatocellular carcionoma and death in patients with chronic hepatitis B-related cirrhosis.

Major finding : Alpha-fetoprotein levels greater than 7 ng/mL (hazard ratio [HR]: 2.84, 95% confidence interval [CI]: 1.73–4.67) and PIVKA-II levels greater than 50 mAU/mL at virological remission significantly predicted the development of HCC (hazard ratios 2.84 and 2.46, respectively).

Study details : The data come from 293 adults with chronic hepatitis B-related cirrhosis; after an average follow-up of 78 months, 76 patient developed HCC and 19 died.

Disclosures: The study was supported by the Ministry of Science and Technology, National Taiwan University Hospital, and the Liver Disease Prevention & Treatment Research Foundation, Taiwan. Lead author Dr. Su disclosed research grant from Gilead Sciences, and serving on speaker's bureaus for AbbVie, Bayer, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp and Dohme, and Takeda.

Source: Su T-H et al. J Formos Med Assoc. 2021 Aug 24. doi: 10.1016/j.jfma.2021.08.003.

Recommended Reading

Prostate cancer: Oral relugolix has efficacy and safety comparable with parenteral degarelix
Federal Practitioner
CRPC: Talazoparib shows response in heavily pretreated patients
Federal Practitioner
CRPC: Nomograms predict outcomes with targeted radionuclide therapy
Federal Practitioner
High-grade prostate cancer: Elevated PSA is linked to high mortality risk
Federal Practitioner
Positive PSMA PET indicates worse metastasis-free survival in recurrent prostate cancer
Federal Practitioner
Prostate cancer: PDE-5 inhibitor use linked to survival benefit
Federal Practitioner
Bone resorption inhibitors extend OS in castration-resistant prostate cancer
Federal Practitioner
Clinical Edge Journal Scan Commentary: HCC September 2021
Federal Practitioner
Antiviral Therapy Improves Hepatocellular Cancer Survival
Federal Practitioner
Adding pembrolizumab shows promise for treating unresectable HCC
Federal Practitioner